• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alterity Therapeutics Limited

    11/21/25 6:29:32 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email
    6-K 1 ea0266703-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-163

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 21, 2025

     

    Alterity Therapeutics Limited

    (Name of Registrant)

     

    Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

    This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

     

     

     

     

     

     

    ALTERITY THERAPEUTICS LIMITED

    (a development stage enterprise)

     

    The following exhibits are submitted:

     

    99.1   Presentation to Annual General Meeting

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Alterity Therapeutics Limited
         
      By: /s/ Geoffrey P. Kempler
        Geoffrey P. Kempler
        Chairman

     

    Date: November 21, 2025

     

    2

    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings

    $ATHE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

    MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia's best healthcare companies.  Presentation details AUSTRALIA PARTICIPANTS:Date:Wednesday, 19 November 2025Time:1:30 p.m. AEDT (Sydney/Melbourne) UNITED STATES PARTICIPANTS:Date:Tuesday, 18 November 2025Time:6:30 p.m. Pacific Time 9:30 p.m. Easte

    11/12/25 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benchmark initiated coverage on Alterity Therapeutics with a new price target

    Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00

    8/20/21 7:25:55 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    SEC Filings

    View All

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/30/26 7:59:40 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/20/26 9:56:00 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/15/26 6:31:43 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

    MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth man

    11/19/24 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    10/31/22 5:29:16 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/26/22 5:16:24 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/1/22 5:21:53 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care